**Core tip:** Human insulin-releasing 1.1B4 β-cell suspensions and psuedoislets were implanted in streptozotocin-diabetic severe combined immune deficient mice to assess their antidiabetic potential. Both cell configurations yielded vascularised, insulin positive β-cell masses. These were associated with beneficial effects on hyperphagia, polydipsia, body weight, hypoinsulinaemia, hyperglycaemia and glucose tolerance. Both treatments were also associated with significant improvements in islet morphology and increased β:α-cell ratio. Pseudoislet recipients displayed gradual glucose normalization, while cell suspension recipients ultimately presented with hypoglycaemic complications. These results provide proof of concept for possible clinical artificial human β-cell psuedoislets, although further work is needed to address the tumourigenicity of clonal cell-lines.

INTRODUCTION
============

Type 1 diabetes mellitus (T1DM) is caused by autoimmune mediated destruction of insulin producing β-cells in the pancreatic islets\[[@B1]\]. Uncontrolled hyperglycaemia leads to debilitating and in some cases life-limiting complications including retinopathy, nephropathy, neuropathy and metabolic ketoacidosis\[[@B2]-[@B5]\]. Protection against these ailments by insulin injections requires frequent monitoring of blood glucose to prevent over - or under-dosage. Hypoglycaemic episodes are not uncommon especially in brittle diabetes where patients often exhibit hypoglycaemia unawareness resulting in dangerous iatrogenic hypoglycaemia\[[@B6]\]. Cellular delivery of insulin achieved by replacement of pancreatic β-cells can help manage diabetes and in some cases eliminate the need for exogenous insulin therapy\[[@B7]\].

At present, the two methods employed to replace lost β-cells in T1DM are pancreatic transplantation (PTx) and islet transplantation (ITx)\[[@B8]\]. PTx involves an invasive procedure performed in combination with kidney transplantation and necessitates chronic immunosuppression to prevent graft rejection\[[@B9],[@B10]\]. In contrast, ITx represents a less invasive alternative to PTx where islets are isolated by enzymatic digestion of donor pancreata and then administered to the recipient by percutaneous infusion into the liver *via* the portal vein\[[@B8]\]. While less risky than whole organ transplantation, ITx is limited by the requirement for immunosuppression to prevent rejection and promote long-term islet graft functionality but the majority of patients still revert to insulin use within five years of treatment\[[@B11],[@B12]\]. Nevertheless, ITx can provide temporary insulin independence and even partial graft function can prevent dangerous hypoglycaemic events\[[@B8],[@B13],[@B14]\]. Unfortunately, pancreatic donors are scarce and current practices often require use of islets from two or more separate donors. This practice is not practical on a large scale and so there is a great impetus to find alternative solutions especially given that implant function also frequently fails with time\[[@B8]\].

One approach to providing a sustainable supply of insulin releasing tissue for transplantation is to generate insulin-producing cells from stem cells or to engineer cell-lines which mimic the functional response of normal human pancreatic β-cells\[[@B15]-[@B18]\]. Over the years, many rodent β-cell lines have been created by methods such as exposure of primary rodent β-cells to radiation or transfection with oncogenic viral vectors such as SV40\[[@B19]-[@B24]\]. While such cell-lines have proven invaluable in basic islet research their xenogeneic properties limit their therapeutic utility. Consequently, more recent endeavours have been focused on the creation of insulin-releasing cell-lines from human β-cells\[[@B25],[@B26]\]. Unfortunately, this has proven to be extremely difficult as human β-cells tend to proliferate poorly and undergo rapid dedifferentiation when cultured *in vitro*. The majority of attempts to develop stable human β-cell lines have yielded cells with limited glucose sensitivity or insufficient insulin content\[[@B27]-[@B32]\].

Extensive functional studies using the novel human β-cell line 1.1B4 created by the electrofusion of freshly isolated human β-cells with immortal PANC1 epithelial partner cells have demonstrated that 1.1B4 cells possess intact cellular mechanisms for insulin production and secretion, and that they are responsive to glucose and other modulators of insulin secretion\[[@B25]\]. The cells also appear to possess similar cytoprotective mechanisms to primary β-cells\[[@B33]-[@B35]\].

Like many β-cell-lines, 1.1B4 cells spontaneously form three dimensional pseudoislets after 5 to 7 d when grown in suspension culture. These pseudoislets are morphologically similar to isolated primary islets and show increased expression of cell-cell communication genes together with remarkable potentiation of insulin secretory responses to glucose and other secretagogues *in vitro*\[[@B25],[@B36]\]. Moreover, 1.1B4 cells showed significantly enhanced resistance to cytotoxicity when configured as pseudoislets compared to monolayers\[[@B37]\]. Transplantation of cells configured as pseudoislets may represent an attractive model to improve graft survival, function and resistance to hyperglycaemia. In the present study the ability of human insulin secreting 1.1B4 cells, administered as single cell suspensions or pseudoislets, to rescue diabetes and restore blood glucose control was studied using severe combined immunodeficient (SCID) mice rendered diabetic by administration of streptozotocin (STZ). These immunodeficient mice were used to prevent rejection of human 1.1B4 cell implants.

MATERIALS AND METHODS
=====================

Cell culture and pseudoislet formation
--------------------------------------

The generation and characterisation of the human 1.1B4 β-cell line has been described previously\[[@B25]\]. The cells were maintained at 37 °C with 5% CO~2~ in RPMI-1640 media (Gibco^®^ Invitrogen, Paisley, United Kingdom) containing 11.1 mol/L glucose and 2.0 mol/L L-glutamine supplemented with 10% (v/v) foetal calf serum (Gibco^®^ Invitrogen, Paisley, United Kingdom) and antibiotics (100 U/mL penicillin and 0.1 g/L streptomycin) (Gibco^®^ Invitrogen, Paisley, United Kingdom). Cells were given fresh media every 2-3 d as necessary and were routinely used from passage 25-35. The cell line is available to purchase from Sigma-Aldrich (Dorset, United Kingdom). To form pseudoislets, 1.1B4 cells were seeded at a density of 1 × 10^5^ cells/well into ultra-low-attachment, six-well, flat-bottomed plates (Corning Inc., NY, United States) with 5-mL/well culture medium. Cells typically formed three-dimensional pseudoislet clusters, each comprising 5000-6000 cells, within 5-7 d of seeding\[[@B37]\].

Animal and surgical procedures
------------------------------

Adult female SCID mice (15-20 wk) were bred and maintained under specific pathogen-free conditions in the Biomedical and Behavioral Research Unit (BBRU) at Ulster University, Coleraine. Food and water were provided *ad libitum* unless specified otherwise. Diabetes was induced by intraperitoneal administration of streptozotocin (165 mg/kg) after an 8 h fast. Hyperglycaemia was controlled with intensive insulin therapy (15 mg/kg body weight intraperitoneal bovine insulin every 8 h) prior to and during the early engraftment period as indicated in the Figures. Suspensions of 1.1B4 cells (1 × 10^7^ cells/mL) were administered in 500 μL serum-free Roswell park memorial institute (RPMI) medium subscapularly into adipose tissue deposit at back of the neck using a 25-G needle. For pseudoislet implantation, harvested pseudoislets were resuspended at a density of 2000 pseudoislets per ml and 500 μL was injected to the same location using an 18-G needle. Control mice received vehicle only. Food intake, water intake and body weight were monitored daily while blood glucose was measured once every 3 d using Ascensia contour glucose strips (Bayar, Uxbridge, United Kingdom). At the end of the study, glucose tolerance was determined by measuring blood glucose and plasma insulin levels after glucose administration (18 mmol/kg *bw i.p*.) at 0 and 15, 30, 60, 90 and 120 min. Finally, terminal blood samples were collected and implants and pancreata were collected for both histology and hormone content assessment. Timeline of the procedures is depicted in Figure [1](#F1){ref-type="fig"}. All animal procedures were performed in adherence to the United Kingdom home office regulations (United Kingdom Animal Scientific Procedures Act 1986) and "Principles of laboratory animal care" (NIH Publication no 86-23, revised 1985).

![Timeline of experiment.](WJD-7-523-g001){#F1}

Biochemical assays
------------------

Lysates of excised cell masses and pancreata were prepared by overnight extraction at 4 °C with acid ethanol (ethanol 75% v/v, water 23.5% v/v and concentrated HCl 1.5% v/v). Protein contents were determined by Bradford assay. Insulin was determined by radioimmunoassay as described previously\[[@B38]\]. Glucagon was determined using glucagon chemiluminescent assay (EZGLU-30K, Millipore, MA, United States) following manufacturer's instructions. Glucose in plasma samples was determined using an Analox GM9 glucose analyzer (Analox, London, United Kingdom).

Immunohistochemistry
--------------------

For peroxidase immunostaining, de-waxed and rehydrated sections were blocked in 0.3% (v/v) H~2~O~2~ in 50% (v/v) methanol for 30 min to quench endogenous peroxidase activity, before incubation at 95 °C in citrate buffer (pH 6.0) for antigen retrieval. After cooling, sections were incubated at 4 °C with mouse anti insulin antibody (1:1000, Abcam, United Kingdom) overnight, and then incubated with ImmPRESS HRP anti mouse IgG (peroxidase) reagent (Vector labs, United Kingdom) and developed with 3, 3'-Diaminobenzidine substrate (Vector labs, United Kingdom). Lastly, sections were counterstained with haematoxylin at 60 °C for 5 min, and slides were cleared with Histo-clear II and mounted with Histomount mounting medium. Slides were viewed using Olympus IX51 inverted microscope and photographed using the SPOT RT-Ke camera (Diagnostic Instruments Inc., Sterling Heights, MI, United States).

For fluorescence immunostaining, following dewaxing, rehydration, antigen retrieval with citrate buffer and blocking with BSA solution, sections were incubated at 4 °C overnight with primary antibodies (mouse anti insulin antibody, ab6995, 1:1000, Abcam; guinea pig anti glucagon antibody, PCA2/4, raised in house; rabbit anti Ki67 antibody, ab15580, 1:100, Abcam) prior to incubation at 37 °C for 45 min with secondary antibody (Alexa Fluor 488/594)\[[@B35],[@B39]\]. Finally, slides were mounted with anti-fade mounting medium and viewed under FITC filter (488 nm) or TRITC filter using a fluorescent microscope (Olympus, model BX51) and photographed using a connected DP70 camera adapter system.

Image analysis
--------------

Closed polygon tool in Cell-F image analysis software (Olympus Soft Imaging Solutions, GmbH) was used to analyze islet parameters including islet, α cell and β cell areas. Number of islets was counted in a blinded fashion and expressed as number per mm^2^ of pancreas. For analysis of islet size distribution, islets smaller than 10000 μm^2^ were considered small, those larger than 10000 μm^2^ but smaller than 25000 μm^2^ were considered medium and those larger than 25000 μm^2^ were considered large. Cells expressing both insulin and either Ki67 or TUNEL were counted and values were expressed as a percentage of the total number of insulin positive cells observed. Approximately 1000 β-cells were analyzed per replicate.

Statistical analysis
--------------------

Results are expressed as mean ± SEM. Groups of data were compared using Student's unpaired *t*-test with two-tailed *P*-values. Groups were considered significant where *P \<* 0.05.

RESULTS
=======

Effects on food and fluid intake, body weight and blood glucose
---------------------------------------------------------------

Streptozotocin diabetes caused significant increases in food and fluid intake when compared to non-diabetic controls (*P \<* 0.05, *P \<* 0.01, *P \<* 0.001, Figure [2A](#F2){ref-type="fig"} and B). Implantation of 1.1B4 cell suspensions or pseudoislets had small inhibitory effects on daily and cumulative food intake (Figure [2A](#F2){ref-type="fig"}). 1.1B4 pseudoislet transplantation significantly (*P \<* 0.05) decreased fluid intake from day 18 post-implantation compared to the marked polydipsia exhibited by diabetic controls (Figure [2B](#F2){ref-type="fig"}). Fluid intake of cell suspension recipients did not significantly differ from control diabetic mice, indicating less effective amelioration of blood glucose control.

![Effects on food and fluid intake, body weight and blood glucose of streptozotocin diabetic severe combined immunodeficient mice implanted with 1.1B4 cells/ pseudoislets. A: Food intake; B: Fluid intake; C: Change in body weight; D: Blood glucose. From day 6-27, all diabetic mice were injected with insulin (15 U/kg bw) every 8 h (Indicated by black bar). At the end of the study, glucose tolerance (E) was determined over a time course of 120 min. Values are mean ± SEM (*n* = 4). ^a^*P* \< 0.05, ^d^*P* \< 0.01 and ^f^*P* \< 0.001 *vs* diabetic control animals; ^g^*P* \< 0.05, ^j^*P* \< 0.01 *vs* 1.1B4 cell suspension recipients.](WJD-7-523-g002){#F2}

Streptozotocin diabetes resulted in significant and progressive body weight loss compared to non-diabetic controls (*P \<* 0.05, *P \<* 0.01, Figure [2C](#F2){ref-type="fig"}). Transplantation of 1.1B4 cells resulted in significantly increased body weight compared to diabetic controls 15 d post transplantation (*P \<* 0.05, Figure [2C](#F2){ref-type="fig"}), while pseudoislets evoked a more gradual increase with values differing significantly from diabetic controls from 24 d post transplantation (*P \<* 0.05, Figure [2C](#F2){ref-type="fig"}).

Streptozotocin diabetes significantly increased blood glucose levels within 3 d compared to non-diabetic controls (*P \<* 0.001, Figure [2D](#F2){ref-type="fig"}). The hyperglycaemia was moderated during the period of insulin treatment but rebounded to very high levels thereafter. Blood glucose was significantly decreased at 12 and 15 d after implantation of 1.1B4 cells (*P \<* 0.001, Figure [2D](#F2){ref-type="fig"}) or pseudoislets (*P \<* 0.05, Figure [2D](#F2){ref-type="fig"}) respectively. From day 12 onwards, a much more moderate fall of blood glucose was observed in the pseudoislet recipient group (*P \<* 0.05, *P \<* 0.01, Figure [2D](#F2){ref-type="fig"}). Indeed, whereas mice receiving 1.1B4 cells were culled at 21 d post-transplantation to avoid severe hypoglycaemia, pseudoislet recipients exhibited normoglycaemia when the study was terminated at 30 d.

Effects on glucose tolerance
----------------------------

Following an 8 h fast and intraperitoneal glucose administration, blood glucose levels of both 1.1B4 cell suspension and pseudoislet recipients were significantly lower than diabetic control animals at all time-points observed (*P \<* 0.01, Figure [2E](#F2){ref-type="fig"}). Furthermore, 1.1B4 cell suspension implants yielded significantly (*P \<* 0.05) lower blood glucose levels than pseudoislet implants or normal control mice (*P \<* 0.05, *P \<* 0.01, Figure [2E](#F2){ref-type="fig"}). Pseudoislet recipients exhibited normal glucose tolerance.

Effects on plasma and pancreatic hormone content
------------------------------------------------

Insulin content of cell suspension and pseudoislet implant did not differ significantly (Figure [3A](#F3){ref-type="fig"}). Streptozotocin diabetes significantly decreased plasma insulin compared to non-diabetic mice (*P \<* 0.001). Insulin concentrations were significantly raised in mice receiving 1.1B4 cell suspension and pseudoislet implants (10.8 and 7.9 fold increases respectively, *P \<* 0.05, *P \<* 0.01, Figure [3B](#F3){ref-type="fig"}). Streptozotocin diabetes also significantly decreased pancreatic insulin content (*P \<* 0.05, Figure [3C](#F3){ref-type="fig"}) which was not altered by transplantation (Figure [3C](#F3){ref-type="fig"}). Plasma and pancreatic glucagon levels of diabetic mice were significantly increased compared to non-diabetic controls (*P \<* 0.05, *P \<* 0.01, Figure [3D](#F3){ref-type="fig"} and E) and this was partly normalized by cell transplantation (*P \<* 0.05, Figure [3D](#F3){ref-type="fig"} and E).

![Insulin content (A) of excised 1.1B4 cell/pseudoislet cell masses and the effects of implantation on plasma insulin (B), pancreatic insulin content (C), plasma glucagon (D) and pancreatic glucagon content (E) of normal and streptozotocin diabetic severe combined immunodeficient mice. Values are mean ± SEM (*n* = 4). ^a^*P* \< 0.05, ^d^*P* \< 0.01, ^e^*P* \< 0.01 *vs* diabetic control animals.](WJD-7-523-g003){#F3}

Effects on pancreatic islets
----------------------------

Representative images showing insulin and glucagon staining in islets of non-diabetic, diabetic and cell/pseudoislet implanted diabetic mice are shown in Figure [4A](#F4){ref-type="fig"}. Histological analysis of the islets showed that streptozotocin markedly diminished islet area, β cell area, β to α cell ratio and number of islets while increasing alpha cell area (*P \<* 0.05, *P \<* 0.01, *P \<* 0.001, Figure [4B](#F4){ref-type="fig"}-F). Islet areas of 1.1B4 cell suspension recipients were marginally decreased compared to diabetic controls (*P \<* 0.05, Figure [4B](#F4){ref-type="fig"}). However, α-cell areas were decreased and both β-cell and β- to α-cell ratios were significantly increased in 1.1B4 cell suspension and pseudoislet recipients (*P \<* 0.05, Figure [4C](#F4){ref-type="fig"}-E). Percentage of smaller islets increased in diabetic mice which was not normalised by cell or pseudoislet transplantation (Figure [4G](#F4){ref-type="fig"}).

![Result of insulin (red) and glucagon (green) staining in islets of non-diabetic and diabetic severe combined immunodeficient mice with or without cell/pseudoislet transplantation. Representative images are shown in A. Islet area (B), β cell area (C), α cell area (D), β to α cell ratio (E), number of islets (F), and islet size distribution (G) were all determined by quantitative histological analysis using cell\^F software. Values are mean ± SEM (*n* = 5). ^a^*P* \< 0.05, ^d^*P* \< 0.01 and ^f^*P* \< 0.001 *vs* diabetic control.](WJD-7-523-g004){#F4}

Representative images showing Ki67/insulin and TUNEL/insulin staining in islets of non-diabetic, diabetic and cell/pseudoislet implanted diabetic mice are shown in Figure [5A](#F5){ref-type="fig"}. Diabetes induction was associated with significant decreases in β-cell Ki67 to TUNEL ratio indicating an increase in the frequency of β-apoptosis and a decrease in β-cell proliferation (*P \<* 0.05, Figure [5B](#F5){ref-type="fig"}-D). Implants did not significantly affect β-cell Ki67 or TUNEL expression.

![Frequency of β-cell proliferation (A) and apoptosis (B) and ratio of Ki67 to TUNEL positive β-cells (C) were determined by histological analysis. Values are mean ± SEM (*n* = 4). Approximately 1000 β-cells were counted per replicate. ^a^*P* \< 0.05 *vs* diabetic controls.](WJD-7-523-g005){#F5}

DISCUSSION
==========

The therapeutic potential of novel 1.1B4 human insulin-releasing β-cells configured as cell suspensions or pseudoislets was assessed by implantation into diabetic SCID mice. 1.1B4 cells exhibit marked decreases in secretory function and viability following prolonged exposure to high levels of glucose\[[@B33],[@B37]\]. As a result, mice with chemically-induced diabetes were given insulin therapy for 9-27 d after STZ to moderate blood glucose levels during the engraftment of implanted 1.1B4 cell suspensions and pseudoislets. As expected, control STZ-treated mice characteristically exhibited hyperphagia, polydipsia, weight loss and marked hyperglycaemia which were temporarily moderated during the period of insulin treatment.

Implantation of 1.1B4 cell suspensions or pseudoislets yielded vascularised cell masses (data not included) which restored plasma insulin concentrations and reversed the hyperglycaemic state. We did not have the opportunity to measure human C-peptide for confirmation but we assume that this insulin was derived from extra-pancreatic source because analysis of pancreatic tissue at end of study revealed severe loss of islet beta cells and cellular insulin in both 1.1B4 cell implanted groups similar to untreated diabetic controls. Furthermore, human insulin and C-peptide were readily detectable in 1.1B4 cells\[[@B25]\]. This was associated with significant beneficial effects on glucose tolerance, body weight and both, food and fluid intakes, but plasma glucagon remained elevated. These results have parallels with previous studies where primary islets were implanted into insulin controlled diabetic animals\[[@B40]-[@B42]\]. However, recipients of 1.1B4 cell suspensions progressed to low blood glucose levels such that these mice were terminated at 21 d after transplantation. In contrast, the anti-hyperglycaemic effects of pseudoislet implants manifested more slowly, achieving stable normoglycaemia without hypoglycaemic complications. Furthermore, energy and fluid balance, body weight, blood glucose and glucose tolerance improved gradually in these mice. This difference is most likely due to improved insulin secretory function in 1.1B4 pseudoislets compared to single isolated cells as described previously *in vitro*\[[@B25],[@B36],[@B37],[@B43]\]. This better regulated insulin release is supported by similar insulin contents of the two types of resected β-cell masses. Nevertheless, part of the difference may also reflect the slower cellular proliferation following pseudoislet implantation.

Administration of STZ to SCID mice was associated with significant decreases in islet number, size and β-cell number together with significant α-cell hyperplasia. These observations accompanied by depletion of pancreatic insulin and enhancement of pancreatic glucagon, mirror previous studies of animal models of diabetes induced by STZ\[[@B35],[@B39],[@B44]-[@B49]\]. Implantation of 1.1B4 cell suspensions did not affect hormone contents but was associated with decreases in α-cell and islet areas but an increase in β-cell area and the β-cell to α-cell ratio. There were no significant changes in β-cell proliferation or apoptosis, so alterations of these processes in islet α-cells merits further study. However, both pancreatic insulin and glucagon were unchanged in transplanted mice. Given the present interest in changes of α cell populations in diabetes\[[@B35],[@B47],[@B49]\], this observation merits further investigation. The effects on pancreatic hormones and islets were similar in pseudoislet recipients but as with the metabolic effects, they were moderate compared with cell suspension recipients.

Both cell suspensions and, to a lesser extent, 1.1B4 pseudoislets developed into cell masses following transplantation. While no obvious signs of metastasis were apparent in either group following post-mortem examination, the tumorigenic nature of the cells remains an obstacle to therapeutic use. 1.1B4 cells configured as pseudoislets exhibited significantly decreased proliferation rates and are self-limiting in size *in vitro*\[[@B36]\]. This might be a consequence of cell-cell contacts playing a role in modulation of proliferation and apoptosis rates. However, it seems likely that an additional factor limiting pseudoislet growth *in vitro* is hypoxia, a common consequence of culturing cell spheroids in static cultures. This view is supported by the ability of MIN6 mouse β-cell pseudoislets cultured in bioreactor with continuous stirring to grow continuously for two wk without exhibiting any signs of hypoxia, reduced functionality, or growth arrest\[[@B50]\]. *In vivo* 1.1B4 cells pseudoislets were able to quickly muster a blood supply which allowed proliferation of the cells. This contrasts with the limited ability of human islets to establish effective vascularisation which is a major hindrance to clinical islet outcomes\[[@B51]\].

A number of groups have investigated potential ways of getting around the issue of tumorigenicity of engineered β-cells which need to be generated in large numbers in culture. The most popular approach is the use of tailored viral vectors which allows the inactivation or excision of oncogenes from the cell-lines genomes to reverse the immortal status of the cells once enough have been generated for use\[[@B17],[@B26],[@B32]\]. If such an approach could potentially be tailored to reverse the tumorigenic status of 1.1B4 cells, the therapeutic qualities observed in this study could be more usefully exploited for the treatment of T1DM. An additional or alternative approach involves the use of implantation devices that are currently under development\[[@B7],[@B52]\]. These devices, such as TheraCyte™ macroencapsulation system and nanofiber-enabled encapsulation devices support cell function by providing good oxygen tension and protection from autoimmune attack, whilst providing against unwanted growth and spread of implanted cells\[[@B7],[@B52],[@B53]\].

To conclude, implantation of human 1.1B4 cells configured as pseudoislets rescued diabetes and significantly improved glucose tolerance, providing stable blood glucose control. Although the results provide proof-of-concept for possible therapeutic use of genetically engineered human β-cells configured as pseudoislets, further work to circumvent the tumorigenic properties of the cells, by genetic manipulation using viral vectors or implantation devices, will be required before such an approach can be realised in a clinical setting.
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This is the first study to show that the implantation of 1.1B4 pseudoislets can reverse diabetes in an animal model and to demonstrate additional beneficial effects of such treatment on the endocrine pancreas.
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These results provide proof-of-concept for possible therapeutic use of genetically engineered human β-cells configured as psuedoislets as an alternative to the unsustainable practice of implanting primary human islets.
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